FDA to Review Letermovir for CMV Disease Prevention in Kidney Transplant Recipients

The FDA has accepted for review two sNDAs for Prevymis (letermovir).

Related Keywords

Nicholas Kartsonis ,Merck Prevymis ,Global Clinical Development ,Merck Research Laboratories ,Drug Administration ,Priority Review ,New Drug Application ,Prescription Drug User Fee Act ,Merck Research ,Accessed February ,